Clinical Trial Library
General Videos
Breast Cancer Trials
Prostate Cancer Trials
Supportive Care Trials
Head And Neck Cancer Trials
Lung Cancer Trials
Kidney Cancer Trials
Early Detection Trials
Immunotherapy Trials
Understanding Clinical Trials
In this video, we cover:
What a clinical trial is: Research studies designed to answer medical questions and improve treatment.
Phases of trials: From early safety studies to large studies comparing standard care vs. new therapies.
Who can join: How eligibility is determined based on diagnosis, health, and other factors.
How trials are run: Randomization, control groups, and data collection explained in plain language.
Why it matters: Clinical trials lead to better treatments, improved survival, and more personalized care.
About the Clinical Trial Consent Process
In this video, we cover:
What informed consent means: Understanding your rights and the purpose of consent in research.
The consent conversation: What doctors and research staff will explain before you agree to join.
Key elements of the consent form: Study purpose, procedures, potential risks and benefits, and your alternatives.
Your choices: Why participation is always voluntary, and how you can withdraw at any time.
Protecting patients: How consent ensures transparency and safeguards throughout the trial
NRG-HN009: Head & Neck Cancer Trial — Weekly Low-Dose vs. High-Dose Cisplatin With Radiation for Locoregionally Advanced SCCHN
Study Overview:
This Phase II/III randomized trial compares weekly low-dose cisplatin versus high-dose cisplatin every 3 weeks, both combined with radiation, for patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). The goal is to balance efficacy and tolerability to improve patient outcomes.
WF-1901: IMPACTS Trial — Using an Internet-Based Program to Improve Pain Management in Cancer Survivors
Study Overview:
WF-1901 tests an online self-management program to help cancer survivors manage persistent, treatment-related pain. The program offers education, coping strategies, and interactive tools designed to improve pain control, daily functioning, and quality of life.
GU012: SAMURAI Trial — Combining Stereotactic Ablative Radiation and Immunotherapy for Advanced Renal Cell Carcinoma
Study Overview:
GU012 evaluates whether adding stereotactic ablative radiation therapy (SABR) to immunotherapy improves tumor control and long-term survival in patients with unresectable metastatic renal cell carcinoma (RCC) compared to immunotherapy alone.
URCC21038: DiRECT Trial — Enhancing Cancer Care Through Diversity by Studying Immunotherapy Outcomes Across Populations
Study Overview:
The DiRECT trial investigates how immune checkpoint inhibitors affect treatment response and survival across diverse racial and ethnic groups. By collecting biological samples and treatment data, researchers aim to understand why some populations respond differently and to reduce disparities in cancer care.
GU013: High Five Trial — Evaluating 5-Fraction SBRT vs. Conventional Radiation for High-Risk Prostate Cancer
Study Overview:
This Phase III trial compares three radiation strategies for men with high-risk prostate adenocarcinoma:
Ultrahypofractionated SBRT (5 sessions)
Moderate hypofractionation
Conventional fractionation
The goal is to determine whether fewer, higher-dose treatments can achieve the same or better cancer control while improving convenience and quality of life.
A012301: LoTAM Trial — Comparing Low-Dose Tamoxifen vs. Standard Endocrine Therapy for Early-Stage Hormone-Positive Breast Cancer
Study Overview:
LoTAM evaluates whether low-dose tamoxifen can be as effective as standard endocrine therapy in preventing recurrence for postmenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer. Researchers are also assessing whether the lower dose reduces adverse events and improves treatment adherence.
A082304: PROSPECT LUNG Trial — Comparing Perioperative vs. Adjuvant Systemic Therapy for Resectable Stage II–IIIB NSCLC
Study Overview:
This Phase III study investigates whether giving systemic therapy before and after surgery (perioperative) improves outcomes compared to the standard approach of post-surgical treatment only (adjuvant) in patients with Stage II–IIIB non-small cell lung cancer (NSCLC).
A012103: OPTIMICE-PCR Trial — Reducing Therapy Intensity in Triple-Negative Breast Cancer After a Complete Response
Study Overview:
This trial focuses on patients with early-stage triple-negative breast cancer (TNBC) who have achieved a pathologic complete response (pCR) after chemotherapy plus pembrolizumab. The study compares close monitoring after surgery versus continuing pembrolizumab treatment for up to 27 weeks to determine whether additional therapy is necessary
NRG-CC014: PREEMPT Trial — Preventative Radiation Therapy vs. Standard Care to Reduce Bone Complications in High-Risk Metastatic Cancer
Study Overview:
NRG-CC014 evaluates whether giving early preventative radiation therapy can lower the risk of complications like bone fractures, spinal cord compression, and severe pain in patients with metastatic cancer and high-risk bone lesions that are not yet causing symptoms.
A012102: Multicancer Early Detection Blood Test Study — Building a National Reference Set to Validate Emerging Screening Technologies
Study Overview:
A012102 evaluates whether creating a large, national reference set of blood samples can help validate multicancer early detection (MCED) tests. These tests aim to detect cancers at earlier, more treatable stages across multiple tumor types, before symptoms appear.
ASPIRE Clinical Trial (A032302): Adding Docetaxel to ADT + Apalutamide for Metastatic Prostate Cancer
In this video we will cover:
Can adding chemotherapy up front improve survival in metastatic prostate cancer?
The ASPIRE Trial (Alliance A032302) is a Phase III clinical study for men with metastatic castrate-sensitive prostate cancer (mCSPC). It compares standard treatment — androgen deprivation therapy (ADT) plus apalutamide — with a more intensive approach that also includes docetaxel chemotherapy.